Rare Disease Focus Marathon targets rare neurological and movement disorders, creating opportunities for co development, licensing, or joint ventures with larger pharma seeking to expand an orphan drug portfolio.

Manufacturing Partnerships As a nimble biopharma with a manufacturing focus, Marathon could attract contract manufacturing, fill finish, and API supply partnerships to scale early stage therapies for rare diseases.

Regulatory Access Advantage The Washington DC presence provides proximity to regulatory bodies, enabling strategic regulatory affairs support and potential accelerations for orphan drug approvals.

Regional Collaboration Network Headquartered near Chicago with offices in New Jersey and DC offers access to regional academic centers CROs and patient groups for trial site recruitment and distribution partnerships.

Strategic Financing Opportunity With modest revenue, Marathon may be open to upfront licensing milestones and strategic investments from larger pharma to accelerate development and commercialization of its pipeline.